Full Press Release Details
• NeOnc’s second concurrent Phase 2 clinical study seeks further safety and preliminary evidence of the biological effects of its lead drug candidate, NEO100™, on certain cancers of the brain and central nervous system.
• Generated by NeOnc’s patented NEO™ technology platform, NEO100-02™ for meningioma indications is intended to target such tumors that occur in membranes surrounding the brain and spinal cord.
• Research of NEO100 advances under FDA Investigative New Drug (IND), Orphan Drug (OD) and Fast-Track status using oral and novel intranasal (via nose) delivery methods.
• Trial highlights the ability of the NEO™ technology platform to produce novel drugs and delivery methods designed to overcome the persistent challenges in delivering chemotherapeutics through the blood-brain barrier.
Westlake Village, CA, August 5, 2024 – NeOnc Technologies Holdings, Inc., a clinical-stage medical biotechnology company, has begun patient enrollment for the Phase 2 clinical trial of NEO100-02™, the company’s first of two drug candidates proceeding through four concurrent clinical trials for various indications and patient populations.
The Phase 2 study of NEO100-02 seeks further safety and preliminary evidence of the biological effects of the novel drug on patients afflicted with residual, progressive, or recurrent high-grade meningioma.
Meningioma is the most common type of benign tumor that forms in the brain. They grow from the membranes that surround the brain and spinal cord, with such growth potentially pressing on the nearby brain, nerves, and blood vessels. Like any tumor, it may become
NeOnc’s CEO and CSO Dr. Thomas Chen
atypical or malignant. Meningiomas may also develop in areas of the brain that are difficult to operate upon, such as at the base of the skull.
Approximately 97 out of every 100,000 people will be diagnosed with meningioma sometime during their lifetime, according to the Cleveland Clinic, with this resulting in more than 170,000 people diagnosed with meningioma annually in the United States.
“Addressing the unique challenges posed by skull-base meningiomas, this trial is tailored to a population with limited alternative treatment options,” commented NeOnc CEO, Thomas Chen, MD, Ph.D. “The difficulty in accessing these tumors frequently results in significant neurological deficits post-surgery, and traditional radiation therapy often proves ineffective.”
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a privately held clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier.
The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status.
The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology, visit neonc.com .
NeOnc Company Contact:
Patrick Walters, COO
NeOnc Technologies Holdings, Inc.
Email Contact
NeOnc Investor Relations:
Ron Both
CMA Investor Relations
Tel (949) 432-7566
Email Contact
NeOnc Media & ESG Contact:
Tim Randall
CMA Media Relations
Tel (949) 432-7572
Email Contact